posted
BIO low price high volume. This stock has no reason to be low, the drug is being produced - so company should be making money soon on sales. Good one to watch.
TMC moved up to 0.68 and couple of days was 0.8 - good new on their side also. Trading on TSX. I think they are trading in US by no idea where......
Just on updated...
GREGDOGG
posted
Hey Wizard, did you see this back between Sept. 03 and Feb. 04 ?????
TradingWizard
posted
I got in for 0.50 (and within 4 days was up to 1.02 something like that).... I have some in my Canadian RRSPs account so again I don't do daytrading...but I see bright future with this drug - claiming very little side effects or none... Good luck....its up today 0.68-0.70 Cnd
GREGDOGG
posted
Gotta go, I'll chat later.
Start selling high and buying low, the stocks you seem to play are perfect for "rolling" not long-term holding.
See ya.
TradingWizard
posted
....NEW NEWS TODAY
Biotech Holdings makes first shipment of Sucanon diabetes drug
VANCOUVER, May 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- (PR NewsWire)
Robert Rieveley, President of Biotech Holdings (the "Company", TSX-V: BIO.V; OTC BB: BIOHF) announced today the first shipment of the Company's Sucanon diabetes drug.
"We are pleased to report that the first shipment of Sucanon diabetes drug has now been sent to Mexico. This portion of our current production will be used for sample packages of Sucanon to be distributed to doctors, pharmacists and buyers for drugstores in Mexico," Mr. Rieveley said.
"Sending this shipment is part of fulfilling the requirements for getting Sucanon marketing in Mexico underway," Mr. Rieveley said.
"More information on our marketing plan, including radio, TV and print advertising purchases for Mexico, including broadcast in some Spanish-language media in the United States, will be reported shortly," Mr. Rieveley added.
World Health Organization data indicate that over 14% of Mexican adults suffer from Type II Diabetes. With a population of over 110 million, Mexico is one of the largest markets in the world for Type II Diabetes drugs. Type II Diabetes affects over 30 million people in Latin America and more than 18 million in North America.
Biotech Holdings' Sucanon is an insulin-sensitizing drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug, in tablet form, improves patients' ability to utilize insulin, the hormone that controls blood sugar levels.
Biotech Holdings has received regulatory approval for sale of the drug in Mexico and Peru as a treatment of Type II Diabetes symptoms. Biotech Holdings has also signed distribution agreements for the drug for Chile, Venezuela, Columbia and Argentina and plans to make regulatory applications for Sucanon in these jurisdictions as well as in Brazil.
If you would you would like to be added to Biotech Holdings' email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp
Biotech Holdings Ltd.'s head office is in Richmond, British Columbia. Biotech Holdings' shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com.
SOURCE Biotech Holdings Ltd.
Austin Rand at Biotech Holdings Ltd., 1-888-216-1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com; To request a free copy of this organization's annual report, please go to http://www.newswire.ca and click on reports@cnw. (BIO. BIOHF)
Copyright (C) 2004 PR Newswire. All rights reserved.
TradingWizard
posted
Bio up 0.10 today (10:09 am)
TradingWizard
posted
Biotech Holdings signs Sucanon Marketing agreement for Mexico
VANCOUVER, Jun 1, 2004 /PRNewswire-FirstCall via COMTEX/ -- (PR NewsWire)
Robert Rieveley, President of Biotech Holdings (the "Company", TSX-V: BIO.V; OTC BB: BIOHF) announced today that the Company has signed an agreement for marketing its Sucanon diabetes drug in Mexico.
"I am pleased to report that our marketing agreement for Mexico has now been signed. Pursuant to the agreement, we will be conducting an intensive campaign, beginning this month, to bring Sucanon to doctors, pharmacists and the public in Mexico," Mr. Rieveley said.
"We will be conducting symposia for doctors, providing Sucanon samples and carrying out an extensive program of doctor visits. We anticipate visiting eighteen hundred doctors in their offices each month," Mr. Rieveley added.
"To make Sucanon as broadly available as possible, our marketing agreement requires that Sucanon will be available for dispensing in at least 45% of all pharmacies in Mexico and will be carried by several national pharmaceutical chains, including Mexico's largest pharmaceutical chain," Mr. Rieveley said.
"To reach diabetic patients directly, Sucanon will be advertised on both national and regional television as well as on some of the top radio shows in Mexico. Since there is a very significant Hispanic market in the U.S., several of these shows, together with Sucanon advertising, will be simulcast in markets in the southern U.S. A Sucanon infomercial and a two-minute Sucanon advertising spot will be produced," Mr. Rieveley said.
"The Mexican market for Type II Diabetes is estimated to be in excess of 20 million persons, with over 10 million of these having been diagnosed and reporting to their doctor. We are looking forward to having the widest possible audience learn of the benefits of Sucanon," Mr. Rieveley added.
Biotech Holdings' Sucanon is an insulin-sensitizing drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug, in tablet form, improves patients' ability to utilize insulin, the hormone that controls blood sugar levels.
Biotech Holdings has received regulatory approval for sale of Sucanon in Mexico and Peru as a treatment of Type II Diabetes symptoms. Biotech Holdings has also signed distribution agreements for the drug for Chile, Venezuela, Columbia and Argentina and plans to make regulatory applications for Sucanon in these jurisdictions as well as in Brazil.
If you would you would like to be added to Biotech Holdings' email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp
Biotech Holdings Ltd.'s head office is in Richmond, British Columbia. Biotech Holdings' shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact: Austin Rand at Biotech Holdings Ltd., 1 (888) 216-1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com.
SOURCE Biotech Holdings Ltd.
Austin Rand at Biotech Holdings Ltd., 1 (888) 216-1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca (BIO. BIOHF)
------------------ 'Alone we can do so little; together we can do so much.' - Helen Keller
TradingWizard
posted
Biotech Holdings completes first Sucanon production order
VANCOUVER, Jun 7, 2004 /PRNewswire-FirstCall via COMTEX/ -- (PR NewsWire)
Robert Rieveley, President of Biotech Holdings (the "Company", TSX-V: BIO.V; OTC BB: BIOHF) announced today that the Company has completed the first production order of its Sucanon diabetes drug.
"I am pleased to report that our first production order is now completed. We have manufactured Sucanon for 1.2 million tablets or 20,000 one-month treatment packages. We project shipping this production to Mexico this week," Mr. Rieveley said.
"The sales value to Biotech of this shipment is in the range of $240,000 US," Mr. Rieveley said.
"Monthly shipments of this volume, providing monthly treatment for 20,000 diabetics, would move us easily into profitability. With 10 million reporting Type II diabetics in Mexico and 10 million unreporting, we believe that Mexico offers tremendous potential for ongoing use of Sucanon as an effective and very safe treatment of Type II Diabetes symptoms. Our plant capacity of up to 400,000 one-month treatment packages can be readily expanded as needed," Mr. Rieveley added.
Biotech Holdings' Sucanon is an insulin-sensitizing drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug, in tablet form, improves patients' ability to utilize insulin, the hormone that controls blood sugar levels.
Biotech Holdings has received regulatory approval for sale of Sucanon in Mexico and Peru as a treatment of Type II Diabetes symptoms. Biotech Holdings has also signed distribution agreements for the drug for Chile, Venezuela, Columbia and Argentina and plans to make regulatory applications for Sucanon in these jurisdictions as well as in Brazil.
Following up on its regulatory approval in Mexico and Peru, the Company expects to make applications shortly in several other jurisdictions in Latin America, including Argentina, Chile, Venezuela.
If you would you would like to be added to Biotech Holdings' email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp
Biotech Holdings Ltd.'s head office is in Richmond, British Columbia. Biotech Holdings' shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1-888-216-1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com.
SOURCE Biotech Holdings Ltd.
For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1-888-216-1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com. To request a free copy of this organization's annual report, please go to http://www.newswire.ca and click on reports@cnw. (BIO. BIOHF)
Copyright (C) 2004 PR Newswire. All rights reserved.
------------------ 'Alone we can do so little; together we can do so much.' - Helen Keller
HasmirFenring
posted
Hey Trading Wizard What are your thoughts on bio right now? Today it has been nice and low, i bought a small amount at .66, I like the new focus of the company, I am certainly no expert but I think that they have hit a huge market with a hopefully needed product imho... what are you thinking for time period...
HasmirFenring
posted
Getting even lower...Is anyone watching this one for another entry point? Market depth doesn't reveal any support to I am hesitant to rely on the chart....Any thoughts?
TradingWizard
posted
I got in this stock at 0.50, it made nice run to 1.24 - never sold. Then slowly start going down and I got some more at 0.95. I think between 0.50-0.65, is a good price to get in - this is my opinion only. The previous runs where relying on start of production of the drug, now the stock settled and I guess next turning point is sales - looks like they are going after good regions with high diabetic population in South America. I bought this stock as a long term holding stock.
------------------ 'Alone we can do so little; together we can do so much.' - Helen Keller
GREGDOGG
posted
Just looked at it, if it goes below .50 I'd be worried
Product looks good, chart looks iffy, 1 year looks good but 5 year looks crappy, tough call....
[This message has been edited by GREGDOGG (edited June 23, 2004).]
TradingWizard
posted
Thanks GREGDOGG for your info (and how are you these days - its been a while). You are correct this is a tough call, but I will make product the priority for now and ignore charts (later). The problem at this moment is that they only are in the marketing stage of their product launch, but once that goes and sales start to come in, I think it will boost the pps evidently.
And here is the latest news:
First Run of Sucanon Tablets Completed, Biotech Holdings Reports VANCOUVER, Jun 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- (PR NewsWire)
Robert Rieveley, President of Biotech Holdings (the "Company", TSX-V: BIO.V; OTC BB: BIOHF) announced today that the first run of Sucanon tablets has been completed.
"I am pleased to report that our manufacturing partner in Mexico has completed the first run of Sucanon tablets. These tablets will be shipped to us this week for quality control and will be blister-packed and boxed as soon as quality control is confirmed," Mr. Rieveley said.
"The tablets in this run will allow us to provide one-month, 60-tablet packages of Sucanon to approximately 2,000 physicians and pharmacists, as part of the launch of Sucanon in Mexico," Mr. Rieveley added.
"I am also pleased to report that we have provided, to our marketing partners in Mexico, detailed materials in English and Spanish for Sucanon infomercial and advertising materials that they are now preparing. In addition to being broadcast for national coverage in Mexico, the infomercials and advertisements are also planned to be simulcast in several major Spanish- speaking markets in the U.S.," Mr. Rieveley said.
Biotech Holdings' Sucanon is an insulin-sensitizing drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug, in tablet form, improves patients' ability to utilize insulin, the hormone that controls blood sugar levels.
Biotech Holdings has received regulatory approval for sale of Sucanon in Mexico and Peru as a treatment of Type II Diabetes symptoms and is planning to make regulatory applications later this year in Argentina, Chile, and Venezuela, to be followed by Brazil. The company also plans to study the potential for finding a U.S. partner and making a regulatory application in the United States for Sucanon as part of a combination therapy.
If you would you would like to be added to Biotech Holdings' email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp
Biotech Holdings Ltd.'s head office is in Richmond, British Columbia. Biotech Holdings' shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com.
SOURCE Biotech Holdings Ltd.
[This message has been edited by TradingWizard (edited June 29, 2004).]
HasmirFenring
posted
Biotech retains Stockgroup Media for "Undervalued Companies" investor information program
09:01 EDT Tuesday, July 06, 2004
VANCOUVER, July 6 /PRNewswire-FirstCall/ - Biotech Holdings (the "Company", BIOHF.OB, BIO.V) announced today that it has retained Stockgroup Media Inc. to provide an investor awareness program as Biotech prepares to launch marketing and distribution of its diabetes drug, Sucanon, in Mexico.
"We believe that our plan to launch Sucanon in Mexico next month, and to make Sucanon available to diabetics in the U.S. through Mexican pharmacies, will mean that there will be news from Biotech over the next several months that will be of great interest to investors," Mr. Rieveley said.
"To get our story out to the broadest investor audience, we will be participating in Stockgroup Media's new information distribution program, "Undervalued Companies Stock Center". This program starts next month and runs through November. Our program with Stockgroup earlier this year was very effective for getting our story to investors and we look forward to building on that success," Mr. Rieveley said.
Biotech Holdings' Sucanon is an insulin-sensitizing drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug, a small tablet taken twice daily, improves patients' ability to utilize insulin, the hormone that controls blood sugar levels.
Biotech Holdings has received regulatory approval for sale of Sucanon in Mexico where 15% of adults - more than 10 million people - have been diagnosed as requiring treatment for Type II Diabetes. The company also plans to study the potential for finding a U.S. partner and making a regulatory application in the United States for Sucanon as part of a combination therapy. Sucanon has also received regulatory approval in Peru and the Company is planning to make regulatory applications later this year in Argentina, Chile, and Venezuela, to be followed by Brazil.
If you would you would like to be added to Biotech Holdings' email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp
Biotech Holdings Ltd.'s head office is in Richmond, British Columbia. Biotech Holdings' shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com.
posted 
